<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "http://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<processing-meta>
<custom-meta-group content-type="composition">
<custom-meta specific-use="newgen" xlink:href="https://www.newgen.co/">
<meta-name>Composition Vendor</meta-name>
<meta-value>Newgen KnowledgeWorks (P) Ltd.</meta-value>
</custom-meta>
</custom-meta-group>
</processing-meta>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS One</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0349672</article-id>
<article-id pub-id-type="publisher-id">PONE-D-26-10765</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Geriatrics</subject><subj-group><subject>Frailty</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Anesthesiology</subject><subj-group><subject>Anesthesia</subject><subj-group><subject>Local and regional anesthesia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject><subj-group><subject>Anesthesia</subject><subj-group><subject>Local and regional anesthesia</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Anesthesiology</subject><subj-group><subject>Anesthesia</subject><subj-group><subject>General anesthesia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject><subj-group><subject>Anesthesia</subject><subj-group><subject>General anesthesia</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Anesthetics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pain management</subject><subj-group><subject>Anesthetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Chronic obstructive pulmonary disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3">
<subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Sedation</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Feasibility of local anesthesia for full-endoscopic spine surgery: A retrospective cohort study of body weight-based thresholds</article-title>
<alt-title alt-title-type="running-head">Safety and feasibility of local anesthesia for FESS: Body weight-based thresholds</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0004-5404-7397</contrib-id>
<name name-style="western">
<surname>Ohshima</surname>
<given-names>Takafumi</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kitahara</surname>
<given-names>Takayuki</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Watanabe</surname>
<given-names>Seiya</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Soeda</surname>
<given-names>Saori</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0001-8795-109X</contrib-id>
<name name-style="western">
<surname>Nakajima</surname>
<given-names>Daiki</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kageyama</surname>
<given-names>Hiroshi</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Morimoto</surname>
<given-names>Masatoshi</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Manabe</surname>
<given-names>Hiroaki</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tezuka</surname>
<given-names>Fumitake</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fujitani</surname>
<given-names>Junzo</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4860-9259</contrib-id>
<name name-style="western">
<surname>Teramoto</surname>
<given-names>Atsushi</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Sairyo</surname>
<given-names>Koichi</given-names>
</name>
<role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Orthopedics, University of Tokushima, Tokushima, Japan</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Orthopaedics, Sapporo Medical University School of Medicine, Sapporo, Japan</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>ONO</surname>
<given-names>KOICHIRO</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Nippon Medical School, JAPAN</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">sairyokun@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>29</day><month>5</month><year>2026</year></pub-date>
<pub-date pub-type="collection"><year>2026</year></pub-date>
<volume>21</volume>
<issue>5</issue>
<elocation-id>e0349672</elocation-id>
<history>
<date date-type="received"><day>11</day><month>3</month><year>2026</year></date>
<date date-type="accepted"><day>3</day><month>5</month><year>2026</year></date>
</history>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>Ohshima et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0349672"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>While transforaminal full-endoscopic spine surgery (TF-FESS) under local anesthesia offers the advantages of real-time neurological feedback and minimized physiological stress, concerns persist regarding whether the procedure can be consistently completed within safe local anesthetic dosage limits in all patient populations. This study evaluated the feasibility and safety of TF-FESS under local anesthesia independent of frailty status using body weight-based safety thresholds for lidocaine.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>We retrospectively identified 108 patients who underwent single-level TF-FESS under local anesthesia and categorized them into a non-frail group (modified Frailty Index-5 [mFI-5] &lt; 2, n = 80) and a frail group (mFI-5 ≥ 2, n = 28). Weight-based thresholds, calculated using actual body weight, were set at 7 mg/kg for non-frail patients and 5 mg/kg for frail patients. The anesthesia protocol consisted of sequential 1% lidocaine injection and conscious sedation. Complications were defined as clinically significant local anesthetic systemic toxicity, postoperative delirium, and permanent nerve root injury, with exclusion of transient intraoperative feedback.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Surgery was successfully completed under local anesthesia in all 108 cases (100%), with continuous verbal communication maintained throughout the procedure. The mean lidocaine dose was 218 ± 40 mg, with no significant difference between groups (p = 0.722). In the frail group, 92.9% of patients remained within the stricter 5 mg/kg threshold. No documented cases of clinically significant local anesthetic systemic toxicity, permanent nerve root injury, or postoperative delirium were observed in either group.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>TF-FESS under local anesthesia appears feasible, with no clinically significant complications observed in this cohort, irrespective of frailty status. Although the dosing thresholds were well-tolerated, they should be interpreted with caution given the study’s retrospective nature. Adherence to weight-based dosing and a standardized conscious sedation protocol is associated with a favorable safety profile while preserving real-time neurological feedback. This strategy may minimize perioperative physiological stress and cognitive risks in an increasingly aging population.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>The author(s) received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="3"/>
<page-count count="11"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec026">Supporting Information</xref> files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>One of the consequence of rapidly aging populations worldwide has been an increasing prevalence of degenerative spinal diseases requiring surgical intervention [<xref ref-type="bibr" rid="pone.0349672.ref001">1</xref>,<xref ref-type="bibr" rid="pone.0349672.ref002">2</xref>]. Multimorbidity and frailty are common among elderly patients, making conventional open surgery under general anesthesia a high-risk proposition because of the potential for perioperative complications, including cardiovascular events and postoperative delirium [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0349672.ref004">4</xref>]. Transforaminal full-endoscopic spine surgery (TF-FESS) has become a leading minimally invasive spine surgery with significant advantages, including less tissue damage, minimal blood loss, and more rapid recovery [<xref ref-type="bibr" rid="pone.0349672.ref005">5</xref>,<xref ref-type="bibr" rid="pone.0349672.ref006">6</xref>].</p>
<p>While local anesthesia (LA) is often preferred for a transforaminal approach to allow real-time neurological feedback [<xref ref-type="bibr" rid="pone.0349672.ref007">7</xref>], general anesthesia remains widely used in many clinical settings to ensure patient comfort and procedural stability [<xref ref-type="bibr" rid="pone.0349672.ref008">8</xref>]. However, use of LA is gaining traction because it minimizes physiological stress and avoids general anesthesia-related risks, particularly in vulnerable populations such as the frail elderly [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0349672.ref009">9</xref>]. The safety of LA is of particular concern in frail patients, whose decreased physiological reserve and potential variations in drug metabolism may narrow the therapeutic window for local anesthetic agents [<xref ref-type="bibr" rid="pone.0349672.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0349672.ref011">11</xref>]. However, despite their clinical importance, empirical data comparing the safety and anesthetic requirements of TF-FESS under LA between frail and non-frail patients remain scarce.</p>
<p>The modified Frailty Index-5 (mFI-5) is a validated and efficient tool for assessment of frailty and predicting postoperative outcomes in various surgical specialties, including spine surgery [<xref ref-type="bibr" rid="pone.0349672.ref012">12</xref>,<xref ref-type="bibr" rid="pone.0349672.ref013">13</xref>]. Use of this index makes it possible to objectively categorize patients and evaluate the feasibility of TF-FESS under LA in high-risk groups. The purpose of this study was to evaluate the safety and clinical outcomes of TF-FESS under LA, specifically focusing on the comparison of local anesthetic dosage and complication rates between frail patients (mFI-5 ≥ 2) and non-frail patients (mFI-5 &lt; 2). Our hypothesis was that TF-FESS under LA could be safely performed in frail patients without increasing the risk of clinically significant local anesthetic systemic toxicity (LAST) or other major complications.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec007">
<title>Ethics statement</title>
<p>The study was approved by the Institutional Review Board of Tokushima University Hospital (approval number 3642) and conducted in accordance with the principles expressed in the Declaration of Helsinki. Because of the retrospective nature of this study, the requirement for written informed consent was waived by the IRB. Instead, informed consent was obtained via the opt-out method, where information regarding the study was disclosed on the hospital’s official website to provide patients with the opportunity to decline participation. All data were pseudonymized before analysis to ensure patient confidentiality. For research purposes, the medical records were accessed between 1 Dec 2025 and 15 Feb 2026. During and after data collection, the authors had no access to information that could identify individual participants.</p>
</sec>
<sec id="sec008">
<title>Study population and variables</title>
<p>We retrospectively identified all patients who underwent TF-FESS under LA at our institution between January 2024 and March 2025. Patients were excluded if they underwent surgeries involving two or more intervertebral levels or if the surgery was indicated for spinal infection.</p>
<p>Baseline demographic and surgical data for these patients were collected from the electronic medical records. The patient data collected included age, sex, actual body weight, relevant comorbidities (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, and congestive heart failure), and functional status (evaluated as a categorical variable). Patient frailty was assessed using the mFI-5 and a corresponding binary frailty indicator [<xref ref-type="bibr" rid="pone.0349672.ref011">11</xref>,<xref ref-type="bibr" rid="pone.0349672.ref012">12</xref>].</p>
<p>Operative variables included the surgical diagnosis, operative level, operative time, and total dose of 1% lidocaine. To ensure the robustness of our safety analysis, specific complications were defined as follows:</p>
</sec>
<sec id="sec009">
<title>Local anesthetic systemic toxicity</title>
<p>Clinically significant LAST was assessed based on the occurrence of classic central nervous system symptoms (e.g., metallic taste, circumoral numbness, tinnitus, agitation, or seizures) or cardiovascular instability (e.g., bradycardia, arrhythmias, or hypotension) during or immediately after the procedure.</p>
</sec>
<sec id="sec010">
<title>Postoperative delirium</title>
<p>Postoperative delirium was defined as any documented episode of acute confusion, disorientation, or altered consciousness recorded in the electronic medical records by nursing or medical staff during the hospital stay. We note that standardized prospective tools, such as the Confusion Assessment Method (CAM), were not utilized in this retrospective review.</p>
</sec>
<sec id="sec011">
<title>Nerve root injury</title>
<p>Nerve root injury was defined strictly as new-onset postoperative motor weakness or sensory deficits that persisted beyond the immediate recovery period. Transient intraoperative leg pain or electric shock-like sensations during the procedure were considered essential components of real-time neurological feedback and were not classified as complications. Intraoperative tolerability measures included the need for intravenous rescue analgesics/sedatives and interruption/abandonment of the procedure as a result of pain.</p>
</sec>
<sec id="sec012">
<title>Anesthetic and sedation protocol</title>
<p>The LA procedure was performed by the primary surgeon before the surgical incision. Following administration of 1% lidocaine into the subcutaneous tissue and fascia, the anesthetic agent was sequentially injected into the facet joint capsule, the inferior vertebral endplate, and the annulus fibrosus of the intervertebral disc. Injections were performed slowly to minimize the risk of rapid systemic absorption.</p>
<p>Vital signs, including peripheral oxygen saturation, electrocardiography, and non-invasive blood pressure, were monitored continuously throughout the procedure. Surgical nursing staff performed real-time clinical assessments for signs of LAST, and intravenous lipid emulsion was readily available in the operating room as a standard safety precaution.</p>
<p>A standardized conscious sedation protocol was used to ensure patient comfort while maintaining the capacity for neurological feedback. This consisted of intravenous administration of pentazocine (15 mg) and hydroxyzine pamoate (25 mg), which was divided into two doses and administered at 15-min intervals. This regimen allowed for an optimal balance between analgesia and preservation of real-time patient communication during the procedure.</p>
</sec>
<sec id="sec013">
<title>Definition of frailty groups</title>
<p>For subgroup analyses, patients were categorized based on their mFI-5 scores. The cohort was divided into a non-frail group (mFI-5 &lt; 2) and a frail group (mFI-5 ≥ 2) for evaluation of the impact of physiological reserve on surgical and anesthetic outcomes.</p>
</sec>
<sec id="sec014">
<title>Safety threshold for local anesthesia</title>
<p>The individual safety limit for the non-frail group was defined as 7 mg/kg of actual body weight [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>]. In contrast, the safety threshold for the frail group was set at a more conservative 5 mg/kg to account for their narrowed therapeutic window [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>]. This lower threshold was established because frail patients often show increased drug absorption rates, reduced clearance, sarcopenia-related loss of drug reservoirs, and heightened pharmacological sensitivity [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0349672.ref010">10</xref>]. The proportion of cases exceeding the respective dose limits was summarized for both the overall cohort and within each frailty group.</p>
</sec>
<sec id="sec015">
<title>Statistical analysis</title>
<p>Continuous variables are summarized as the mean ± standard deviation and categorical variables (including the proportion of cases exceeding the dose limit) as the number (percentage). Between-group comparisons (non-frail vs. frail) were performed using the Welch two-sample <italic>t</italic>-test for continuous variables and the chi-squared test or Fisher’s exact test or Fisher’s exact test for categorical variables as appropriate. Linear regression analysis was performed to visualize the relationship between actual body weight and the total lidocaine dose administered. The statistical analyses were performed using Python software (libraries including pandas, NumPy, and SciPy). All statistical tests were two-sided, and a p-value of &lt; 0.05 was considered statistically significant. The minimal underlying dataset is provided as <xref ref-type="supplementary-material" rid="pone.0349672.s001">S1 data</xref>.</p>
</sec>
<sec id="sec016">
<title>Reporting guidelines</title>
<p>The study was conducted and reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for cohort studies.</p>
</sec>
</sec>
<sec id="sec017" sec-type="results">
<title>Results</title>
<sec id="sec018">
<title>Study population and baseline characteristics</title>
<p>A total of 150 patients underwent TF-FESS during the study period. After 42 exclusions, (surgeries involving two or more intervertebral levels, n = 35; spinal infection, n = 7), the study cohort included 108 patients, with 80 (74.1%) categorized into the non-frail group (mFI-5 &lt; 2) and 28 (25.9%) into the frail group (mFI-5 ≥ 2) (<xref ref-type="fig" rid="pone.0349672.g001">Fig 1</xref>). The mean age of the overall cohort was 61.9 ± 18.0 years, and 64 patients (59.3%) were male. The frail group was significantly older than the non-frail group (74.5 years ± 10.6 vs. 57.5 ± 18.0 years, p &lt; 0.001). There was no significant between-group difference in sex distribution (p = 0.685) or mean body weight (67.7 ± 13.1 kg vs. 66.8 ± 12.3 kg, p = 0.739).</p>
<fig id="pone.0349672.g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0349672.g001</object-id><label>Fig 1</label><caption><title>Flow Diagram of Patient Selection.</title><p>In total, 108 of the 150 patients screened between January 2024 and March 2025 met the study inclusion criteria. Participants were categorized into a non-frail group (mFI-5 &lt; 2, n = 80) and a frail group (mFI-5 ≥ 2, n = 28) based on the mFI-5 score. Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HT, hypertension; mFI-5, modified Frailty Index-5.</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.g001" xlink:type="simple"/></fig>
<p>Consistent with the frailty classification, the prevalence of each of the comorbidities assessed was significantly higher in the frail group than in the non-frail group (diabetes mellitus, 60.7% vs. 6.2%, p &lt; 0.001; hypertension, 78.6% vs. 21.2%, p &lt; 0.001; chronic obstructive pulmonary disease, 14.3% vs. 1.2%, p = 0.016; chronic heart failure, 53.6% vs. 0.0%, p &lt; 0.001; and dependent functional status (10.7% vs. 0.0%, p = 0.016). Furthermore, the estimated safety limit for LA was significantly lower in the frail group (334 ± 62 mg vs. 474 ± 92 mg, p &lt; 0.001). The baseline demographic and clinical characteristics are summarized in <xref ref-type="table" rid="pone.0349672.t001">Table 1</xref>.</p>
<table-wrap id="pone.0349672.t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0349672.t001</object-id><label>Table 1</label><caption><title>Patient demographics and baseline characteristics.</title></caption>
<alternatives><graphic id="pone.0349672.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.t001" xlink:type="simple"/><table><colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="left">Total<break/><break/>cohort<break/><break/>(n = 108)</th>
<th align="left">Non-frail<break/><break/>group<break/><break/>(n = 80)</th>
<th align="left">Frail<break/><break/>group<break/><break/>(n = 28)</th>
<th align="left">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Demographic data</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Age (years)</td>
<td align="left">61.9 ± 18.0</td>
<td align="left">57.5 ± 18.0</td>
<td align="left">74.5 ± 10.6</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">Male sex</td>
<td align="left">64 (59.3%)</td>
<td align="left">46 (57.5%)</td>
<td align="left">18 (64.3%)</td>
<td align="left">0.685</td>
</tr>
<tr>
<td align="left">Weight (kg)</td>
<td align="left">67.4 ± 12.9</td>
<td align="left">67.7 ± 13.1</td>
<td align="left">66.8 ± 12.3</td>
<td align="left">0.739</td>
</tr>
<tr>
<td align="left">Estimated limit of LA (mg)</td>
<td align="left">438 ± 105</td>
<td align="left">474 ± 92</td>
<td align="left">333.8 ± 62</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left"><bold>Comorbidity</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Diabetes mellitus</td>
<td align="left">22 (20.4%)</td>
<td align="left">5 (6.2%)</td>
<td align="left">17 (60.7%)</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">Hypertension</td>
<td align="left">39 (36.1%)</td>
<td align="left">17 (21.2%)</td>
<td align="left">22 (78.6%)</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">COPD</td>
<td align="left">5 (4.6%)</td>
<td align="left">1 (1.2%)</td>
<td align="left">4 (14.3%)</td>
<td align="left">0.016</td>
</tr>
<tr>
<td align="left">Chronic heart failure</td>
<td align="left">15 (13.9%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">15 (53.6%)</td>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">Dependent functional status</td>
<td align="left">3 (2.8%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">3 (10.7%)</td>
<td align="left">0.016</td>
</tr>
<tr>
<td align="left">mFI-5 score</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">&lt;0.001</td>
</tr>
<tr>
<td align="left">0</td>
<td align="left">57 (52.8%)</td>
<td align="left">57 (71.2%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">1</td>
<td align="left">23 (21.3%)</td>
<td align="left">23 (28.8%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">2</td>
<td align="left">23 (21.3%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">23 (82.1%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">3</td>
<td align="left">5 (4.6%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">5 (17.9%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">4</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">5</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
</tbody>
</table>
</alternatives></table-wrap>
<p>Data are presented as the number (percentage) unless otherwise indicated. Abbreviations: COPD, chronic obstructive pulmonary disease; LA, local anesthesia; mFI-5, modified Frailty Index-5</p>
</sec>
<sec id="sec019">
<title>Surgical characteristics and intraoperative data</title>
<p>The surgical diagnoses primarily included lumbar disc herniation (65.7%), followed by lumbar lateral recess stenosis (17.6%) and lumbar foraminal stenosis (16.7%). The most frequently operated levels were L5/<xref ref-type="supplementary-material" rid="pone.0349672.s001">S1</xref> (47.2%) and L4/5 (35.2%). There was no significant difference in the distribution of surgical diagnoses (p = 0.369) or the operative level (p = 0.125) between the non-frail and frail groups.</p>
<p>The mean operative time for the cohort overall was 83.8 ± 20.2 min, and estimated blood loss was minimal (4.6 ± 4.2 mL). Between-group comparisons found no significant difference in operative time between the non-frail and frail groups (84.5 ± 21.4 min vs. 81.6 ± 16.5 min, p = 0.467). Although the non-frail group had slightly greater estimated blood loss (5.0 ± 4.5 mL vs. 3.4 ± 3.1 mL), this difference reached only borderline significance (p = 0.050) and was not considered clinically meaningful. The surgical data are detailed in <xref ref-type="table" rid="pone.0349672.t002">Table 2</xref>.</p>
<table-wrap id="pone.0349672.t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0349672.t002</object-id><label>Table 2</label><caption><title>Surgical characteristics and operative outcomes.</title></caption>
<alternatives><graphic id="pone.0349672.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.t002" xlink:type="simple"/><table><colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left">Total cohort<break/><break/>(n = 108)</th>
<th align="left">Non-frail group<break/><break/>(n = 80)</th>
<th align="left">Frail group<break/><break/>(n = 28)</th>
<th align="left">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Surgical data</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Diagnosis</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">0.369</td>
</tr>
<tr>
<td align="left">Lumbar disc herniation</td>
<td align="left">71 (65.7%)</td>
<td align="left">53 (66.2%)</td>
<td align="left">18 (64.3%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Lumbar foraminal stenosis</td>
<td align="left">18 (16.7%)</td>
<td align="left">15 (18.8%)</td>
<td align="left">3 (10.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Lumbar lateral recess stenosis</td>
<td align="left">19 (17.6%)</td>
<td align="left">12 (15.0%)</td>
<td align="left">7 (25.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Operated level</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">0.125</td>
</tr>
<tr>
<td align="left">L2/3</td>
<td align="left">6 (5.6%)</td>
<td align="left">2 (2.5%)</td>
<td align="left">4 (14.3%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">L3/4</td>
<td align="left">13 (12.0%)</td>
<td align="left">10 (12.5%)</td>
<td align="left">3 (10.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">L4/5</td>
<td align="left">38 (35.2%)</td>
<td align="left">28 (35.0%)</td>
<td align="left">10 (35.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">L5/S1</td>
<td align="left">51 (47.2%)</td>
<td align="left">40 (50.0%)</td>
<td align="left">11 (39.3%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"><bold>Intraoperative data</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Operative time (min)</td>
<td align="left">83.8 ± 20.2</td>
<td align="left">84.5 ± 21.4</td>
<td align="left">81.6 ± 16.5</td>
<td align="left">0.467</td>
</tr>
<tr>
<td align="left">Blood loss (mL)</td>
<td align="left">4.6 ± 4.2</td>
<td align="left">5.0 ± 4.5</td>
<td align="left">3.4 ± 3.1</td>
<td align="left">0.05</td>
</tr>
<tr>
<td align="left">Local anesthesia, lidocaine</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Total volume (mg)</td>
<td align="left">218 ± 40</td>
<td align="left">219 ± 41</td>
<td align="left">216 ± 37</td>
<td align="left">0.722</td>
</tr>
<tr>
<td align="left">Safety limit Exceeded</td>
<td align="left">2 (1.9%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">2 (7.1%)</td>
<td align="left">0.065</td>
</tr>
<tr>
<td align="left"><bold>Complications</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left">&gt;0.999</td>
</tr>
<tr>
<td align="left">LAST symptoms</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Nerve root injury</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Postoperative delirium</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Conversion to general anesthesia</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left">0 (0.0%)</td>
<td align="left"/>
</tr>
</tbody>
</table>
</alternatives></table-wrap>
<p>Data are presented as the mean ± standard deviation or as the number (percentage) as appropriate. Abbreviation: LAST, local anesthesia systemic toxicity</p>
</sec>
<sec id="sec020">
<title>Safety and outcomes of local anesthesia</title>
<p>In all 108 cases (100%), continuous verbal communication with the patient was successfully maintained throughout the procedure, and the surgery was completed under LA without any need for conversion to general anesthesia. The mean total dose of lidocaine administered intraoperatively was 218 ± 40 mg, with no significant difference observed between the non-frail and frail groups (219 ± 41 mg vs. 216 ± 37 mg, p = 0.722). Evaluation of the total administered volume against the prespecified weight-based safety limits (7 mg/kg for non-frail patients and 5 mg/kg for frail patients) identified only 2 patients (1.9%) in the overall cohort in whom the respective thresholds were exceeded. Subgroup analysis revealed that no patients (0.0%) in the non-frail group exceeded the limit, whereas 2 patients (7.1%) in the frail group exceeded the stricter 5 mg/kg threshold (<xref ref-type="fig" rid="pone.0349672.g002">Fig 2</xref>). This difference did not reach statistical significance (p = 0.065). Linear regression analysis demonstrated that lidocaine dosing trends were nearly identical between the non-frail and frail groups. While the regression lines remained generally below the institutional thresholds for the majority of the cohort, the frail regression line converged toward and slightly intersected the 5 mg/kg limit in the lowest body weight range (<xref ref-type="fig" rid="pone.0349672.g002">Fig 2</xref>).</p>
<fig id="pone.0349672.g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0349672.g002</object-id><label>Fig 2</label><caption><title>Relationship Between Total Lidocaine Dosage and Actual Body Weight Relative to Frailty-Adjusted Safety Limits (n = 108).</title><p>The individual scatter plots represent the total dose of lidocaine (mg) administered during the procedure. The dashed gray line indicates the conventional safety limit for non-frail patients (7 mg/kg), while the dashed black line represents the stricter safety threshold (5 mg/kg) applied to frail patients (mFI-5 ≥ 2). The thin solid lines represent the linear regression of actual doses for each group. Gray circles denote non-frail patients (mFI-5 &lt; 2), and black triangles denote frail patients. Two frail cases slightly exceeded the 5 mg/kg threshold; no local anesthesia systemic toxicity symptoms were observed in these cases. Abbreviation: mFI-5, modified Frailty Index-5.</p></caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.g002" xlink:type="simple"/></fig>
<p>Importantly, the procedure had an excellent safety profile. Regardless of frailty status and whether or not the LA safety threshold was exceeded, there were no documented cases of clinically significant LAST symptoms, nerve root injury, postoperative delirium, or conversion to general anesthesia across the entire cohort (p &gt; 0.999 for all complications). No intravenous rescue analgesics/sedatives were required, and no procedures were interrupted or abandoned because of intolerable pain. Given the zero-event nature of these outcomes, the upper bound of the 95% confidence interval for the event rate was approximately 3.4% for the overall cohort (0/108) and 12.3% for the frail subgroup (0/28).</p>
</sec>
</sec>
<sec id="sec021" sec-type="conclusions">
<title>Discussion</title>
<p>This study showed that TF-FESS under LA was feasible in this cohort, including patients categorized as frail. Notably, across our entire cohort of 108 patients, there were no documented instances of clinically significant LAST, postoperative delirium, permanent nerve root injury, or need for conversion to general anesthesia. These findings suggest that our weight-based LA dosing protocol used I this study was tolerated within this cohort irrespective of frailty status, although the retrospective design and absence of serum lidocaine measurements warrant cautious interpretation.</p>
<sec id="sec022">
<title>Safety of local anesthesia and weight-based dosing thresholds</title>
<p>A primary concern during TF-FESS under LA is the risk of LAST, particularly in elderly or frail patients, in whom drug metabolism is potentially altered [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0349672.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0349672.ref014">14</xref>]. To address this concern, we implemented weight-based safety thresholds, namely, 7 mg/kg for the non-frail group and a more conservative 5 mg/kg for the frail group calculated based on actual body weight. While these thresholds exceed the 4.5 mg/kg limit for plain lidocaine specified in the U.S. Food and Drug Administration (FDA)-approved labeling, our clinical observations suggest they are well-tolerated in the specific context of TF-FESS [<xref ref-type="bibr" rid="pone.0349672.ref003">3</xref>,<xref ref-type="bibr" rid="pone.0349672.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0349672.ref015">15</xref>]. In the non-frail group (n = 80), 100% of patients remained within their safety limit. In the frail group (n = 28), the 5 mg/kg threshold was complied with in 92.9% of cases; although this limit was exceeded slightly in two frail cases because of operative requirements, no clinical symptoms of toxicity were observed. This consistent safety profile across both groups could potentially be explained by the specific anatomical and vascular characteristics of the surgical site. It is hypothesized that the systemic absorption of lidocaine from the subcutaneous tissue and fascia is relatively slow. Furthermore, a substantial volume of lidocaine was administered into the facet joint capsule. The dense fibrous structure of the joint capsule is hypothesized to act as a structural barrier, potentially sequestering part of the anesthetic agent within the intra-articular space and limiting its rapid diffusion to the surrounding extra-capsular tissues, which are more highly vascularized. By restricting immediate access to the systemic circulation in this manner, the joint capsule may help mitigate a rapid increase in intravascular lidocaine concentrations, potentially resulting a more gradual systemic uptake. This, combined with the poorly vascularized nature of the vertebral endplates and intradiscal spaces might further limit rapid systemic entry, although pharmacological studies measuring serum concentrations are required to confirm this mechanism [<xref ref-type="bibr" rid="pone.0349672.ref010">10</xref>,<xref ref-type="bibr" rid="pone.0349672.ref015">15</xref>]. Our data suggest that these weight-based thresholds may serve as a useful clinical benchmark for minimizing the risk of clinically significant LAST in patients undergoing TF-FESS under LA.</p>
<p>However, the interpretation of the 0% incidence of LAST in this study should be cautious. The retrospective design and reliance on medical record documentation primarily reflect the absence of documented, clinically significant LAST requiring medical intervention rather than the complete absence of all LAST-related symptoms. Additionally, the conscious sedation protocol using pentazocine and hydroxyzine could have potentially masked early, mild neurological signs of toxicity, such as metallic taste or circumoral numbness, which might have skewed the reported safety data.</p>
<p>Regarding the frailty spectrum, it is important to note that our frail group (mFI-5 ≥ 2) predominantly consisted of patients with mild frailty (mFI-5 = 2, 82.1%). The study lacked patients with severe frailty (mFI-5 ≥ 4), which may limit the generalizability of our findings to the most vulnerable populations. However, it is noteworthy that we applied the same conservative 5 mg/kg safety threshold to these mildly frail patients as would be used for more severely frail individuals. The fact that the vast majority of these patients were successfully managed within this stricter limit, with dosing trends remaining consistent and generally below the threshold. Further underscores the safety margin of our protocol. Nevertheless, our results highlight that TF-FESS under LA is a viable and low-stress alternative for mildly frail patients who might otherwise face higher risks under general anesthesia.</p>
</sec>
<sec id="sec023">
<title>Clinical safety: Prevention of postoperative delirium and nerve root injury</title>
<p>The complete absence of documented postoperative delirium and nerve root injury across our entire cohort of 108 patients represents a noteworthy clinical observation. Postoperative delirium is a common and distressing complication in elderly patients undergoing spinal surgery under general anesthesia [<xref ref-type="bibr" rid="pone.0349672.ref004">4</xref>]. As shown in <xref ref-type="table" rid="pone.0349672.t003">Table 3</xref>, Tacconi et al. reported a 14.5% postoperative delirium rate under general anesthesia in an elderly cohort, whereas no cases occurred under spinal anesthesia [<xref ref-type="bibr" rid="pone.0349672.ref016">16</xref>]. Although direct comparison is limited by differences in patient age and surgical techniques among these studies, our findings suggest that TF-FESS under LA may offer similar potential advantages in a broader surgical population. The retrospective identification of delirium through medical records without standardized tools like the Confusion Assessment Method may have under-detected hypoactive cases. By mitigating the physiological stress associated with general anesthesia and maintaining the patient’s conscious state, this approach suggests a potential for minimizing the risk of postoperative cognitive decline, even in individuals with frailty.</p>
<table-wrap id="pone.0349672.t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0349672.t003</object-id><label>Table 3</label><caption><title>Selected reports of perioperative complications in patients who underwent lumbar spine surgery.</title></caption>
<alternatives><graphic id="pone.0349672.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.t003" xlink:type="simple"/><table><colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Procedure</th>
<th align="left">Anesthesia method</th>
<th align="left">N</th>
<th align="left">Mean age, years</th>
<th align="left">Postoperative delirium rate</th>
<th align="left">Nerve root injury rate</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Present study</td>
<td align="left">FESS</td>
<td align="left">LA</td>
<td align="left">108</td>
<td align="left">61.9</td>
<td align="left">0% (0.0-3.4%)</td>
<td align="left">0% (0.0-3.4%)</td>
</tr>
<tr>
<td align="left">Wu et al. [<xref ref-type="bibr" rid="pone.0349672.ref018">18</xref>]</td>
<td align="left">PELD</td>
<td align="left">GA</td>
<td align="left">36</td>
<td align="left">48.8</td>
<td align="left">–</td>
<td align="left">8.30%</td>
</tr>
<tr>
<td align="left">Ren et al. [<xref ref-type="bibr" rid="pone.0349672.ref019">19</xref>]</td>
<td align="left">PELD</td>
<td align="left">GA</td>
<td align="left">41</td>
<td align="left">48.8</td>
<td align="left">–</td>
<td align="left">14.60%</td>
</tr>
<tr>
<td align="left">Tacconi et al. [<xref ref-type="bibr" rid="pone.0349672.ref017">17</xref>]</td>
<td align="left">PELD</td>
<td align="left">GA vs SA</td>
<td align="left">27 vs 48</td>
<td align="left">79.6</td>
<td align="left">14.5% vs 0.0%</td>
<td align="left">8%</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot>
<fn id="t003fn001"><p>Values for the present study are presented as percentage (95% confidence interval).</p></fn>
<fn id="t003fn002"><p>Abbreviations: FESS, full-endoscopic spine surgery; GA, general anesthesia; LA, local anesthesia; PELD, percutaneous endoscopic lumbar discectomy; SA, spinal anesthesia.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Furthermore, the 0% nerve root injury rate suggests that TF-FESS under LA can be performed with a favorable safety profile. In contrast with historical data for endoscopic surgery under general anesthesia, where injury rates reached as high as 14.6% even in younger populations (<xref ref-type="table" rid="pone.0349672.t003">Table 3</xref>) [<xref ref-type="bibr" rid="pone.0349672.ref017">17</xref>,<xref ref-type="bibr" rid="pone.0349672.ref018">18</xref>], use of LA allowed for continuous real-time neurological feedback from the patient [<xref ref-type="bibr" rid="pone.0349672.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0349672.ref008">8</xref>]. This “biological monitoring” was effective regardless of frailty status, ensuring that any proximity to neural structures was immediately communicated to the surgeon [<xref ref-type="bibr" rid="pone.0349672.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0349672.ref008">8</xref>,<xref ref-type="bibr" rid="pone.0349672.ref019">19</xref>]. The consistency of these results across our entire cohort underscores the potential of TF-FESS under LA not only as a viable alternative for high-risk patients but also as a valuable strategy for improving procedural safety in degenerative spinal surgery.</p>
</sec>
<sec id="sec024">
<title>Limitations</title>
<p>This study has several limitations. First, it had a retrospective, single-center design and a relatively small sample size in the frail group (n = 28), which primarily consisted of mildly frail patients. While no major complications were observed, larger multicenter prospective studies are needed to confirm the generalizability of our findings. Second, we did not measure serum lidocaine concentrations; therefore, our assessment of local anesthetic safety remains based on clinical observations. Third, the possibility of under-detection of postoperative delirium and mild LAST symptoms as a consequence of the retrospective nature of the research cannot be excluded. Given that these outcomes were identified by review of medical records rather than standardized prospective screening tools, such as the Confusion Assessment Method, subclinical or hypoactive delirium and transient systemic toxicity might have been overlooked. However, it is important to note that no clinically significant episodes (i.e., those requiring medical intervention, causing safety concerns, or impacting the clinical course) were documented throughout the study period. Moreover, mild central nervous system symptoms of LAST could have been partially masked by the effects of the conscious sedation protocol. Fourth, the long-term clinical outcomes beyond the perioperative period were not evaluated. Future research should compare the long-term functional recovery and mortality rates between TF-FESS under LA and TF-FESS under general anesthesia in the frail population.</p>
</sec>
</sec>
<sec id="sec025" sec-type="conclusions">
<title>Conclusion</title>
<p>TF-FESS under LA appears to be a safe and feasible surgical option within this study cohort for both frail and non-frail patients. This is supported by the absence of documented clinically significant LAST, postoperative delirium, and permanent nerve root injury in our study population. Adherence with a weight-based LA dosing protocol, specifically a conservative 5 mg/kg threshold calculated based on actual body weight for frail individuals, is associated with a favorable safety profile, even in patients with multiple comorbidities. Avoiding general anesthesia and using real-time neurological feedback may help to minimize perioperative physiological stress and potentially enhance procedural safety. The findings of this study suggest that TF-FESS under LA may represent a potentially valuable and reliable strategy for managing degenerative spinal diseases in an increasingly aging and high-risk population.</p>
</sec>
<sec id="sec026" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="pone.0349672.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.s001" xlink:type="simple">
<label>S1 data</label>
<caption>
<p>Minimal underlying dataset.</p>
<p>This excel file contains the anonymized raw clinical data used for the analysis in this study.</p>
<p>(XLSX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0349672.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ju</surname> <given-names>CI</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>SM</given-names></name>. <article-title>Complications and Management of Endoscopic Spinal Surgery</article-title>. <source>Neurospine</source>. <year>2023</year>;<volume>20</volume>(<issue>1</issue>):<fpage>56</fpage>–<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14245/ns.2346226.113" xlink:type="simple">10.14245/ns.2346226.113</ext-link></comment> <object-id pub-id-type="pmid">37016854</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fjeld</surname> <given-names>OR</given-names></name>, <name name-style="western"><surname>Grøvle</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Helgeland</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Småstuen</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Solberg</surname> <given-names>TK</given-names></name>, <name name-style="western"><surname>Zwart</surname> <given-names>J-A</given-names></name>, <etal>et al</etal>. <article-title>Complications, reoperations, readmissions, and length of hospital stay in 34 639 surgical cases of lumbar disc herniation</article-title>. <source>Bone Joint J</source>. <year>2019</year>;101-B(<issue>4</issue>):<fpage>470</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1302/0301-620X.101B4.BJJ-2018-1184.R1" xlink:type="simple">10.1302/0301-620X.101B4.BJJ-2018-1184.R1</ext-link></comment> <object-id pub-id-type="pmid">30929479</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cuvillon</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lefrant</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Gricourt</surname> <given-names>Y</given-names></name>. <article-title>Considerations for the Use of Local Anesthesia in the Frail Elderly: Current Perspectives</article-title>. <source>Local Reg Anesth</source>. <year>2022</year>;<volume>15</volume>:<fpage>71</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2147/LRA.S325877" xlink:type="simple">10.2147/LRA.S325877</ext-link></comment> <object-id pub-id-type="pmid">35982729</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pan</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>The risk factors associated with delirium after lumbar spine surgery in elderly patients</article-title>. <source>Quant Imaging Med Surg</source>. <year>2019</year>;<volume>9</volume>(<issue>4</issue>):<fpage>700</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21037/qims.2019.04.09" xlink:type="simple">10.21037/qims.2019.04.09</ext-link></comment> <object-id pub-id-type="pmid">31143661</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Di</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Percutaneous endoscopic lumbar discectomy for lumbar disc herniation</article-title>. <source>J Clin Neurosci</source>. <year>2016</year>;<volume>33</volume>:<fpage>19</fpage>–<lpage>27</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jocn.2016.01.043" xlink:type="simple">10.1016/j.jocn.2016.01.043</ext-link></comment> <object-id pub-id-type="pmid">27475315</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alvi</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Kerezoudis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wahood</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Goyal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bydon</surname> <given-names>M</given-names></name>. <article-title>Operative Approaches for Lumbar Disc Herniation: A Systematic Review and Multiple Treatment Meta-Analysis of Conventional and Minimally Invasive Surgeries</article-title>. <source>World Neurosurg</source>. <year>2018</year>;<volume>114</volume>:391-407.e2. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.wneu.2018.02.156" xlink:type="simple">10.1016/j.wneu.2018.02.156</ext-link></comment> <object-id pub-id-type="pmid">29548960</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sairyo</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Egawa</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Matsuura</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Higashino</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sakai</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>State of the art: Transforaminal approach for percutaneous endoscopic lumbar discectomy under local anesthesia</article-title>. <source>J Med Invest</source>. <year>2014</year>;<volume>61</volume>(3–4):<fpage>217</fpage>–<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2152/jmi.61.217" xlink:type="simple">10.2152/jmi.61.217</ext-link></comment> <object-id pub-id-type="pmid">25264038</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mooney</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Laskay</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Erickson</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Salehani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mahavadi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ilyas</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>General vs Local Anesthesia for Percutaneous Endoscopic Lumbar Discectomy (PELD): A Systematic Review and Meta-Analysis</article-title>. <source>Global Spine J</source>. <year>2023</year>;<volume>13</volume>(<issue>6</issue>):<fpage>1671</fpage>–<lpage>88</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/21925682221147868" xlink:type="simple">10.1177/21925682221147868</ext-link></comment> <object-id pub-id-type="pmid">36564907</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sairyo</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yamashita</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Tezuka</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Morimoto</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Manabe</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Sugiura</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Strengths and Merits of Transforaminal Full-Endoscopic Lumbar Spine Surgery Under the Local Anesthesia: A Review Article</article-title>. <source>J Minim Invasive Spine Surg Tech</source>. <year>2024</year>;<volume>9</volume>(Suppl 2):S143–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21182/jmisst.2024.01193" xlink:type="simple">10.21182/jmisst.2024.01193</ext-link></comment></mixed-citation></ref>
<ref id="pone.0349672.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El-Boghdadly</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Pawa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Chin</surname> <given-names>KJ</given-names></name>. <article-title>Local anesthetic systemic toxicity: current perspectives</article-title>. <source>Local Reg Anesth</source>. <year>2018</year>;<volume>11</volume>:<fpage>35</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2147/LRA.S154512" xlink:type="simple">10.2147/LRA.S154512</ext-link></comment> <object-id pub-id-type="pmid">30122981</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Okada</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Inoue</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Adachi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ito</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Adachi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Soyama</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Five-item Modified Frailty Index in Elderly Patients Undergoing Laparoscopic Colorectal Surgery Predicts Postoperative Complications</article-title>. <source>Cancer Diagn Progn</source>. <year>2024</year>;<volume>4</volume>(<issue>6</issue>):<fpage>729</fpage>–<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.21873/cdp.10388" xlink:type="simple">10.21873/cdp.10388</ext-link></comment> <object-id pub-id-type="pmid">39502614</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patel</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Elali</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Coban</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Changoor</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>NV</given-names></name>, <name name-style="western"><surname>Sinha</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>The 5-factor modified Frailty Index (mFI-5) predicts adverse outcomes after elective Anterior Lumbar Interbody Fusion (ALIF)</article-title>. <source>N Am Spine Soc J</source>. <year>2022</year>;<volume>13</volume>:<fpage>100189</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xnsj.2022.100189" xlink:type="simple">10.1016/j.xnsj.2022.100189</ext-link></comment> <object-id pub-id-type="pmid">36579159</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsiouris</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hammoud</surname> <given-names>ZT</given-names></name>, <name name-style="western"><surname>Velanovich</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Hodari</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Borgi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rubinfeld</surname> <given-names>I</given-names></name>. <article-title>A modified frailty index to assess morbidity and mortality after lobectomy</article-title>. <source>J Surg Res</source>. <year>2013</year>;<volume>183</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jss.2012.11.059" xlink:type="simple">10.1016/j.jss.2012.11.059</ext-link></comment> <object-id pub-id-type="pmid">23273884</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zheng</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>H</given-names></name>. <article-title>Anesthesia methods for full-endoscopic lumbar discectomy: a review</article-title>. <source>Front Med (Lausanne)</source>. <year>2023</year>;<volume>10</volume>:<fpage>1193311</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2023.1193311" xlink:type="simple">10.3389/fmed.2023.1193311</ext-link></comment> <object-id pub-id-type="pmid">37663652</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamaya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tezuka</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Sugiura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takeuchi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Manabe</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Morimoto</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Risk Factor for Additional Intravenous Medication during Transforaminal Full-endoscopic Lumbar Discectomy under Local Anesthesia</article-title>. <source>Neurol Med Chir (Tokyo)</source>. <year>2021</year>;<volume>61</volume>(<issue>3</issue>):<fpage>236</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2176/nmc.oa.2020-0275" xlink:type="simple">10.2176/nmc.oa.2020-0275</ext-link></comment> <object-id pub-id-type="pmid">33504730</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tacconi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Baldo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Merci</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Serra</surname> <given-names>G</given-names></name>. <article-title>Transforaminal percutaneous endoscopic lumbar discectomy: outcome and complications in 270 cases</article-title>. <source>J Neurosurg Sci</source>. <year>2020</year>;<volume>64</volume>(<issue>6</issue>):<fpage>531</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.23736/S0390-5616.18.04395-3" xlink:type="simple">10.23736/S0390-5616.18.04395-3</ext-link></comment> <object-id pub-id-type="pmid">29582973</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Clinical efficacy of general anesthesia versus local anesthesia for percutaneous transforaminal endoscopic discectomy</article-title>. <source>Front Surg</source>. <year>2023</year>;<volume>9</volume>:<fpage>1076257</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fsurg.2022.1076257" xlink:type="simple">10.3389/fsurg.2022.1076257</ext-link></comment> <object-id pub-id-type="pmid">36684360</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ren</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Comparison of the Safety and Effectiveness of Percutaneous Endoscopic Lumbar Discectomy for Treating Lumbar Disc Herniation Under Epidural Anesthesia and General Anesthesia</article-title>. <source>Neurospine</source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>254</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14245/ns.1938366.183" xlink:type="simple">10.14245/ns.1938366.183</ext-link></comment> <object-id pub-id-type="pmid">32054145</object-id></mixed-citation></ref>
<ref id="pone.0349672.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bajaj</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Yap</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Derman</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Konakondla</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kashlan</surname> <given-names>ON</given-names></name>, <name name-style="western"><surname>Telfeian</surname> <given-names>AE</given-names></name>, <etal>et al</etal>. <article-title>Comparative analysis of perioperative characteristics and early outcomes in transforaminal endoscopic lumbar diskectomy: general anesthesia versus conscious sedation</article-title>. <source>Eur Spine J</source>. <year>2023</year>;<volume>32</volume>(<issue>8</issue>):<fpage>2896</fpage>–<lpage>902</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00586-023-07792-4" xlink:type="simple">10.1007/s00586-023-07792-4</ext-link></comment> <object-id pub-id-type="pmid">37450041</object-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0349672.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0349672.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>ONO</surname>
<given-names>KOICHIRO</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>KOICHIRO ONO</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pone.0349672" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">6 Apr 2026</named-content></p>
<p>--&gt;</p>
<p>PONE-D-26-10765</p>
<p>Safety and feasibility of local anesthesia for full-endoscopic spine surgery: A retrospective cohort study of body weight-based thresholds</p>
<p>PLOS One</p>
<p>Dear Dr. Sairyo,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>==============================</p>
<p>ACADEMIC EDITOR:</p>
<p>Thank you for submitting this clinically relevant manuscript. The study addresses an important practical question, and the dataset may be informative. However, a major revision is required before the manuscript can be reconsidered.</p>
<p>Several conclusions are currently stated more strongly than the retrospective design can support. In particular, the 7 mg/kg and 5 mg/kg lidocaine thresholds should be presented more cautiously and more clearly distinguished from established safety limits. The interpretation of LAST should also be revised, as the present data support the absence of documented clinically significant LAST rather than the complete absence of LAST. In addition, the frailty spectrum within the cohort should be clarified, as the frail group appears to consist predominantly of mildly frail patients.</p>
<p>For a revised submission, please: (1) temper the Abstract, Discussion, and Conclusion accordingly; (2) clarify whether dosing was based on actual or ideal body weight; (3) expand the limitations regarding retrospective ascertainment of LAST and postoperative delirium, including the potential masking effect of conscious sedation; and (4) carefully review the pharmacologic rationale and the accuracy of references and comparative statements, including Table 3.</p>
<p>Although one reviewer suggested a minor revision, a major revision is considered more appropriate because these issues affect the framing and interpretation of the manuscript’s main conclusions.</p>
<p>==============================</p>
<p>Please submit your revised manuscript by May 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>Please include the following items when submitting your revised manuscript:</p>
<list list-type="bullet"><list-item><p>A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
</list-item>
<list-item>
<p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
</list-item>
<list-item>
<p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
</list-item>
</list>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" xlink:type="simple">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link ext-link-type="uri" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" xlink:type="simple">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
<p>As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Dr. KOICHIRO ONO</p>
<p>Academic Editor</p>
<p>PLOS One</p>
<p>--&gt;</p>
<p>Journal Requirements:</p>
<p>When submitting your revision, we need you to address these additional requirements.</p>
<p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
<p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" xlink:type="simple">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p>
<p>2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/supporting-information" xlink:type="simple">http://journals.plos.org/plosone/s/supporting-information</ext-link>.</p>
<p>3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.</p>
<p>4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p>--&gt;<bold>Comments to the Author</bold></p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;2. Has the statistical analysis been performed appropriately and rigorously? --&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: N/A</p>
<p>**********</p>
<p>--&gt;3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;5. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--&gt;</p>
<p>Reviewer #1: This retrospective cohort study examines the safety and feasibility of transforaminal full-endoscopic spine surgery (TF-FESS) under local anesthesia in frail versus non-frail patients using body weight-based lidocaine dosing thresholds. While the topic is clinically relevant and addresses an important gap in the literature, there are significant methodological concerns, inconsistencies with established evidence, and issues with completeness and accuracy of references that require in my opinion major revisions before this manuscript can be considered for publication.</p>
<p>1. The authors propose 7 mg/kg for non-frail patients and 5 mg/kg for frail patients as safety thresholds, citing reference (Cuvillon et al., 2022). However, FDA-approved labeling for lidocaine without epinephrine specifies a maximum dose of 4.5 mg/kg, not exceeding 300 mg total. The 7 mg/kg threshold cited by the authors applies only to lidocaine WITH epinephrine, which significantly delays systemic absorption. (Lidocaine Hydrochloride. FDA Drug Label.</p>
<p>Food and Drug Administration. Updated date: 2026-01-16.). Please provide pharmacological justification for any deviation from standard dosing</p>
<p>2. The authors report 0% incidence of LAST, which is presented as a major finding. However, their definition of LAST is problematic: The retrospective design and reliance on medical record documentation (rather than prospective screening) creates high risk of under-detection, which the authors acknowledge only briefly in limitations. The claim of 0% LAST is not credible without prospective, systematic assessment. The authors should reframe this as "no clinically significant LAST requiring intervention" rather than claiming complete absence. Please revise the definition of LAST to acknowledge the spectrum of severity, explicitly state that mild LAST symptoms may have been masked by sedation, tone down claims about safety profile given methodological limitations and add this as a major limitation in the discussion .</p>
<p>3. Questionable Validity of mFI-5 Cutoff: The authors use mFI-5 ≥ 2 to define frailty, but the literature shows: mFI-5 is a continuous variable with incremental risk at each level and most studies use mFI-5 as a continuous predictor or stratify into three groups (0, 1, ≥2). The dichotomization at ≥2 is somewhat arbitrary and may not represent the optimal threshold for anesthetic risk stratificationAdditionally, only 5 patients (4.6%) had mFI-5 = 3, and none had mFI-5 = 4 or 5. This means the "frail" group is predominantly mFI-5 = 2 (82.1%), representing mild frailty at best. The study lacks patients with severe frailty, limiting generalizability.</p>
<p>4. No citation for the conscious sedation protocol (pentazocine + hydroxyzine); No pharmacological references supporting the claim that subcutaneous/fascial/disc injection sites have slow systemic absorption, Limited references on LAST in spine surgery specifically</p>
<p>Reviewer #2: The study provides valuable clinical evidence supporting the safety of transforaminal full-endoscopic spine surgery (TF-FESS) under local anesthesia (LA) in frail populations. The 100% completion rate and zero incidence of Local Anesthetic Systemic Toxicity (LAST) are encouraging. However, the retrospective nature and the lack of serum concentration data for lidocaine limit the pharmacological conclusions. I recommend Minor Revision to address these technical nuances.</p>
<p>Recommendations to the Authors</p>
<p>1.While the study utilizes weight-based thresholds safety limits were set at 7 mg/kg for non-frail patients and 5 mg/kg for frail patients, the authors should specify if these limits were calculated based on actual body weight or ideal body weight, as this is critical for obese or sarcopenic patients</p>
<p>2.The authors hypothesize that slow systemic absorption from poorly vascularized tissues prevents toxicity. The manuscript would be strengthened by citing specific pharmacokinetic literature that supports lidocaine's behavior in the spinal epidural and intradiscal space</p>
<p>3.The study defines postoperative delirium based on medical record reviews rather than a standardized prospective tool like the Confusion Assessment Method (CAM). The authors must more explicitly acknowledge the risk of under-detecting hypoactive delirium in the limitations section.</p>
<p>4.The protocol in the surgeries included pentazocine and hydroxyzine. The authors should discuss whether these sedatives could have masked early neurological signs of mild LAST (e.g., metallic taste or lightheadedness), potentially skewing the safety data.</p>
<p>5.Figure 2 is excellent for visualizing the "safety zone". I suggest adding a trend line or 95% confidence interval to the scatter plot to further illustrate the distribution of dosing relative to the thresholds.</p>
<p>**********</p>
<p>--&gt;6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>.--&gt;</p>
<p>Reviewer #1: <bold>Yes:</bold> Alex Alfieri, M.D., Ph.D.</p>
<p>Hirslanden AndreasClinic</p>
<p>Cham, ZG Switzerland</p>
<p>Reviewer #2: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>To ensure your figures meet our technical requirements, please review our figure guidelines: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/figures" xlink:type="simple">https://journals.plos.org/plosone/s/figures</ext-link></p>
<p>You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation" xlink:type="simple">https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.</ext-link></p>
<p>NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0349672.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0349672.r002</article-id>
<title-group>
<article-title>Author response to Decision Letter 1</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0349672" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj002" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0349672.r001" object-id-type="doi" object-type="decision-letter"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="author-response-date">13 Apr 2026</named-content></p>
<p>Dear Editor and Reviewers,</p>
<p>We would like to thank you for the thoughtful and constructive feedback on our manuscript entitled "Safety and feasibility of local anesthesia for full-endoscopic spine surgery: A retrospective cohort study of body weight-based thresholds."</p>
<p>We have carefully reviewed each comment and have revised the manuscript accordingly. Specifically, we have adopted a more cautious tone in our conclusions, clarified our local anesthesia safety thresholds relative to FDA labeling, and provided detailed pharmacological and anatomical justifications for our observations. Below are our point-by-point responses to the comments.</p>
<p>Changes in Authorship</p>
<p>We would like to inform the Editorial Office that Dr. Atsushi Teramoto has been added as a co-author to this revised manuscript. Dr. Teramoto provided significant intellectual contributions during the revision process, particularly in the critical appraisal of the pharmacological and anatomical interpretations within the Discussion section. He also provided oversight of the data re-analysis and helped refine the manuscript's tone to address the reviewers’ concerns. All authors, including the newly added co-author, have approved this change and the final version of the manuscript.</p>
<p>Response to Editor’s Comments</p>
<p>Comment: The conclusions are stated more strongly than the retrospective design can support.</p>
<p>Response: We have revised the manuscript to adopt a more conservative and cautious tone. Throughout the text, we have replaced "achievement" with "observation" and "inherent safety" with "favorable safety profile". We have also added the phrase "within this study cohort" to acknowledge the limitations of our single-center, retrospective data.</p>
<p>Response to Reviewer #1</p>
<p>Point 1: The safety thresholds used (7 mg/kg and 5 mg/kg) exceed the FDA-approved limit of 4.5 mg/kg for plain lidocaine.</p>
<p>Response: We appreciate this critical point. We have added a dedicated section in the Discussion to address this. We explicitly state that our thresholds exceed the FDA-approved labeling for plain lidocaine. However, we provide a pharmacological rationale for the tolerance observed in TF-FESS, noting that the dense fibrous structure of the facet joint capsule may act as a barrier that facilitates the sequestration of the anesthetic, leading to more gradual systemic uptake compared to more vascularized tissues.</p>
<p>Point 2: The retrospective identification of LAST and delirium might be under-reported, and conscious sedation could mask early symptoms.</p>
<p>Response: We agree and have addressed this as a major limitation. We have clarified that our results reflect the absence of "clinically significant" LAST episodes. Furthermore, we have added a statement acknowledging that our conscious sedation protocol (pentazocine and hydroxyzine) could have masked early neurological signs of toxicity. We also noted that the absence of standardized tools like the Confusion Assessment Method (CAM) might have led to an under-detection of hypoactive delirium.</p>
<p>Response to Reviewer #2</p>
<p>Point 1: Clarify if the thresholds were calculated based on actual, ideal, or adjusted body weight.</p>
<p>Response: We have clarified throughout the manuscript, including the Abstract , Methods , and Conclusion, that all weight-based thresholds were calculated using actual body weight.</p>
<p>Point 2: The frail group is predominantly composed of mildly frail patients.</p>
<p>Response: We have addressed this in the Discussion and Limitations. We specified that 82.1% of our frail group were categorized as mildly frail (mFI-5 = 2). We now emphasize that our results demonstrate high safety even when applying conservative thresholds (5 mg/kg) to this mildly frail population.</p>
<p>Point 3: Table 3 compares heterogeneous populations (different ages and techniques).</p>
<p>Response: To address the statistical uncertainty of our 0% event rate, we have added 95% confidence intervals (0.0–3.4%) to Table 3. We have also added a caveat in the Discussion stating that "direct comparison is limited by differences in patient age and surgical techniques" among the cited studies.</p>
<p>We believe that these extensive revisions, which incorporate more rigorous statistical analysis and a refined pharmacological discussion, have significantly strengthened the scientific rigor and clinical relevance of our study. We hope that the revised manuscript now meets the high standards for publication in PLOS ONE. Thank you once again for the opportunity to improve our work.</p>
<p>Sincerely,</p>
<p>Koichi Sairyo, MD, PhD Corresponding Author Department of Orthopedics, University of Tokushima 3-18-15 Kuramoto, Tokushima 770-8503, Japan E-mail: sairyokun@hotmail.com</p>
<supplementary-material id="pone.0349672.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0349672.s003" xlink:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="aggregated-review-documents" id="pone.0349672.r003" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0349672.r003</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>ONO</surname>
<given-names>KOICHIRO</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>KOICHIRO ONO</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pone.0349672" document-id-type="doi" document-type="article" id="rel-obj003" link-type="peer-reviewed-article"/>
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p><named-content content-type="letter-date">4 May 2026</named-content></p>
<p>Safety and feasibility of local anesthesia for full-endoscopic spine surgery: A retrospective cohort study of body weight-based thresholds</p>
<p>PONE-D-26-10765R1</p>
<p>Dear Dr. Sairyo,</p>
<p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
<p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
<p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/" xlink:type="simple">Editorial Manager®</ext-link> and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact <ext-link ext-link-type="uri" xlink:href="https://plos.my.site.com/s/" xlink:type="simple">billing support</ext-link>.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p>
<p>Kind regards,</p>
<p>KOICHIRO ONO</p>
<p>Academic Editor</p>
<p>PLOS One</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p>--&gt;<bold>Comments to the Author</bold></p>
<p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--&gt;</p>
<p>Reviewer #1: All comments have been addressed</p>
<p>Reviewer #2: (No Response)</p>
<p>**********</p>
<p>--&gt;2. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;3. Has the statistical analysis been performed appropriately and rigorously? --&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
<p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing" xlink:type="simple">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
<p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>**********</p>
<p>--&gt;6. Review Comments to the Author</p>
<p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--&gt;</p>
<p>Reviewer #1: The Authors revised the manuscript according the reviewers` indications. I have no more concerns.</p>
<p>best</p>
<p>Reviewer #2: The revision has improved the manuscript meaningfully — tone is more cautious, FDA labeling is acknowledged, CIs have been added, and the limitations section is more honest.</p>
<p>However, I still have few comments.</p>
<p>1. The study is fundamentally underpowered to demonstrate "safety."</p>
<p>A 0/108 event rate yields a 95% upper CI of ~3.4% overall and ~12.3% in the frail subgroup (the authors now report this, which is appreciated). A complication rate of up to ~12% in frail patients is not reassuring, and the manuscript should not characterize this as evidence of safety. The title and Conclusion still imply a stronger inference than the data support. I recommend:</p>
<p>Revising the title to something like "Feasibility of TF-FESS under local anesthesia: a single-center retrospective cohort" and removing "Safety" from the title, or qualifying it.</p>
<p>In the Abstract Conclusion, replacing "appears to be a safe and feasible surgical option" with "appears feasible, with no clinically significant complications observed in this small cohort.</p>
<p>2. Reference 16 (Ashton 1992) is cited to support the facet capsule barrier hypothesis, but that paper describes nerve fibers and neuropeptides in the capsule — it does not establish the capsule as a pharmacokinetic barrier. The citation does not support the claim made.</p>
<p>**********</p>
<p>--&gt;7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" xlink:type="simple">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy" xlink:type="simple">Privacy Policy</ext-link>.--&gt;</p>
<p>Reviewer #1: <bold>Yes:</bold> Alex Alfieri, M.D., Ph.D., Switzerland</p>
<p>Reviewer #2: No</p>
<p>**********</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0349672.r004" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0349672.r004</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western"><surname>ONO</surname>
<given-names>KOICHIRO</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2026</copyright-year>
<copyright-holder>KOICHIRO ONO</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license>
</permissions>
<related-object document-id="10.1371/journal.pone.0349672" document-id-type="doi" document-type="article" id="rel-obj004" link-type="peer-reviewed-article"/>
</front-stub>
<body>
<p>PONE-D-26-10765R1</p>
<p>PLOS One</p>
<p>Dear Dr. Sairyo,</p>
<p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.</p>
<p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p>
<p>* All references, tables, and figures are properly cited</p>
<p>* All relevant supporting information is included in the manuscript submission,</p>
<p>* There are no issues that prevent the paper from being properly typeset</p>
<p>You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p>
<p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p>
<p>You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at <ext-link ext-link-type="uri" xlink:href="https://explore.plos.org/phishing" xlink:type="simple">https://explore.plos.org/phishing</ext-link>.</p>
<p>If we can help with anything else, please email us at customercare@plos.org.</p>
<p>Thank you for submitting your work to PLOS ONE and supporting open access.</p>
<p>Kind regards,</p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. KOICHIRO ONO</p>
<p>Academic Editor</p>
<p>PLOS One</p>
</body>
</sub-article>
</article>